Episode Details
Back to Episodes
Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals
Published 1 year, 4 months ago
Description
Interim CEO Magda Jonikas describes Mosaic's platform and the rationale behind these two targets the company has licensed in.